137 related articles for article (PubMed ID: 17896839)
1. Rituximab: in rheumatoid arthritis.
Frampton JE; Scott LJ
BioDrugs; 2007; 21(5):333-41: discussion 342. PubMed ID: 17896839
[TBL] [Abstract][Full Text] [Related]
2. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
[TBL] [Abstract][Full Text] [Related]
3. [Targeting CD20 in rheumatoid arthritis].
Saito K; Tanaka Y
Nihon Rinsho; 2007 Jul; 65(7):1243-9. PubMed ID: 17642239
[TBL] [Abstract][Full Text] [Related]
4. [B cell depletion therapy using anti-CD20 antibodies in rheumatoid arthritis].
Yukawa N; Mimori T
Clin Calcium; 2007 Apr; 17(4):569-76. PubMed ID: 17404487
[TBL] [Abstract][Full Text] [Related]
5. Rituximab for rheumatoid arthritis.
Palylyk-Colwell E; McGahan L
Issues Emerg Health Technol; 2006 Sep; (89):1-4. PubMed ID: 17014062
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
Edwards JC; Szczepanski L; Szechinski J; Filipowicz-Sosnowska A; Emery P; Close DR; Stevens RM; Shaw T
N Engl J Med; 2004 Jun; 350(25):2572-81. PubMed ID: 15201414
[TBL] [Abstract][Full Text] [Related]
8. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
Mease PJ; Revicki DA; Szechinski J; Greenwald M; Kivitz A; Barile-Fabris L; Kalsi J; Eames J; Leirisalo-Repo M
J Rheumatol; 2008 Jan; 35(1):20-30. PubMed ID: 18050385
[TBL] [Abstract][Full Text] [Related]
9. B cells in rheumatoid arthritis: from hypothesis to the clinic.
Keystone EC
Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii8-ii12. PubMed ID: 15851525
[TBL] [Abstract][Full Text] [Related]
10. B cell-directed therapy in rheumatoid arthritis--clinical experience.
Panayi GS
J Rheumatol Suppl; 2005 Feb; 73():19-24; discussion 29-30. PubMed ID: 15693112
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis.
Keystone E; Fleischmann R; Emery P; Furst DE; van Vollenhoven R; Bathon J; Dougados M; Baldassare A; Ferraccioli G; Chubick A; Udell J; Cravets MW; Agarwal S; Cooper S; Magrini F
Arthritis Rheum; 2007 Dec; 56(12):3896-908. PubMed ID: 18050221
[TBL] [Abstract][Full Text] [Related]
12. Long term treatment of rheumatoid arthritis with rituximab.
Caporali R; Caprioli M; Bobbio-Pallavicini F; Bugatti S; Montecucco C
Autoimmun Rev; 2009 Jun; 8(7):591-4. PubMed ID: 19393205
[TBL] [Abstract][Full Text] [Related]
13. Rituximab for the treatment of rheumatoid arthritis.
Bagust A; Boland A; Hockenhull J; Fleeman N; Greenhalgh J; Dundar Y; Proudlove C; Kennedy T; Moots R; Williamson P; Dickson R
Health Technol Assess; 2009 Sep; 13 Suppl 2():23-9. PubMed ID: 19804686
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
Emery P; Fleischmann R; Filipowicz-Sosnowska A; Schechtman J; Szczepanski L; Kavanaugh A; Racewicz AJ; van Vollenhoven RF; Li NF; Agarwal S; Hessey EW; Shaw TM;
Arthritis Rheum; 2006 May; 54(5):1390-400. PubMed ID: 16649186
[TBL] [Abstract][Full Text] [Related]
15. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.
Lal P; Su Z; Holweg CT; Silverman GJ; Schwartzman S; Kelman A; Read S; Spaniolo G; Monroe JG; Behrens TW; Townsend MJ
Arthritis Rheum; 2011 Dec; 63(12):3681-91. PubMed ID: 22127691
[TBL] [Abstract][Full Text] [Related]
16. Rituximab: a new therapeutic alternative in rheumatoid arthritis.
Sibilia J; Gottenberg JE; Mariette X
Joint Bone Spine; 2008 Oct; 75(5):526-32. PubMed ID: 18571968
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M
Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial.
Mease PJ; Cohen S; Gaylis NB; Chubick A; Kaell AT; Greenwald M; Agarwal S; Yin M; Kelman A
J Rheumatol; 2010 May; 37(5):917-27. PubMed ID: 20194448
[TBL] [Abstract][Full Text] [Related]
19. [Rituximab treatment of rheumatoid arthritis: new evidence].
Nasonov EL
Ter Arkh; 2009; 81(6):82-91. PubMed ID: 19663200
[TBL] [Abstract][Full Text] [Related]
20. B cell-targeted therapy for rheumatoid arthritis: an update on the evidence.
Looney RJ
Drugs; 2006; 66(5):625-39. PubMed ID: 16620141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]